ArticleBMC pharmacology & toxicology2025
The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.
Jianhui Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.